Investigating the role of a specific microRNA in multiple sclerosis and its animal model.
The pathogenic role of miR-92a in the regulation of T helper cell responses in EAE and MS
This study is looking at how a tiny molecule called miR-92a affects the immune system in people with multiple sclerosis (MS) and in a related animal model, to find new ways to help improve treatments for MS.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10770555 on NIH RePORTER |
What this research studies
This research focuses on understanding how a microRNA called miR-92a influences immune responses in multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE). The study aims to uncover the mechanisms by which miR-92a affects the balance between different types of immune cells, particularly T helper cells, which play a crucial role in inflammation and immune regulation. By examining the expression levels of miR-92a in patients and animal models, researchers hope to identify potential therapeutic targets that could improve treatment outcomes for individuals with MS.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with multiple sclerosis or those exhibiting symptoms of experimental autoimmune encephalomyelitis.
Not a fit: Patients with other neurological disorders unrelated to autoimmune mechanisms may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that better manage inflammation and immune responses in patients with multiple sclerosis.
How similar studies have performed: Previous research has shown promising results in targeting microRNAs for therapeutic purposes in autoimmune diseases, indicating potential success for this approach.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Gopal, Murugaiyan — Brigham and Women's Hospital
- Study coordinator: Gopal, Murugaiyan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.